HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Stock
Equities
600671
CNE000000BF3
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.89 CNY | +4.59% |
|
+11.82% | -23.76% |
| Sales 2022 | 109M 15.03M 20.55M | Sales 2023 | 122M 16.81M 22.98M | Capitalization | 1.42B 196M 268M |
|---|---|---|---|---|---|
| Net income 2022 | -67M -9.25M -12.64M | Net income 2023 | -38M -5.24M -7.17M | EV / Sales 2022 | 11.3 x |
| Net Debt 2022 | 73.65M 10.16M 13.9M | Net Debt 2023 | 16.8M 2.32M 3.17M | EV / Sales 2023 | 11.8 x |
| P/E ratio 2022 |
-17.3
x | P/E ratio 2023 |
-37.1
x | Employees | 371 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 38.72% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.59% | ||
| 1 week | +11.82% | ||
| Current month | -2.74% | ||
| 1 month | -1.77% | ||
| 3 months | -21.60% | ||
| 6 months | -14.60% | ||
| Current year | -23.76% |
1 week
7.55
8.93
1 month
7.5510.10
Current year
7.5511.81
1 year
7.2112.41
3 years
7.1712.41
5 years
5.9718.70
10 years
5.9739.71
| Managers | Title | Age | Since |
|---|---|---|---|
Xu Yu Xu
CEO | Chief Executive Officer | 46 | 23-09-26 |
Hong Jian Yu
DFI | Director of Finance/CFO | 46 | 23-09-26 |
Guo Jun Dang
BRD | Director/Board Member | 37 | 21-05-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hua Cheng
BRD | Director/Board Member | 55 | 91-12-31 |
Guo Jun Dang
BRD | Director/Board Member | 37 | 21-05-25 |
Hong Jian Yu
DFI | Director of Finance/CFO | 46 | 23-09-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 8.89 | +4.59% | 1,173,353 |
| 24-04-25 | 8.5 | +1.07% | 455,150 |
| 24-04-24 | 8.41 | +4.86% | 784,701 |
| 24-04-23 | 8.02 | -2.08% | 415,201 |
| 24-04-22 | 8.19 | +3.02% | 1,302,016 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd is a China based company principally engaged in the research and development, production and sales of pharmaceuticals and related health products. The Company is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The Company's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The Company mainly operates its business in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.76% | 149M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600671 Stock
